3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      AAV-encoded CaV2.2 peptide aptamer CBD3A6K for primary sensory neuron-targeted treatment of established neuropathic pain

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="P1">Transmission of pain signals from primary sensory neurons to secondary neurons of the central nervous system is critically dependent on presynaptic voltage-gated calcium channels. Calcium channel-binding domain 3 (CBD3), derived from the collapsin response mediator protein 2 (CRMP2), is a peptide aptamer that is effective in blocking N-type voltage-gated calcium channel (Ca <sub>V</sub>2.2) activity. We previously reported that recombinant adeno-associated virus (AAV)-mediated restricted expression of CBD3 affixed to enhanced green fluorescent protein (EGFP) in primary sensory neurons prevents the development of cutaneous mechanical hypersensitivity in a rat neuropathic pain model. In this study, we tested whether this strategy is effective in treating established pain. We constructed AAV6-EGFP-CBD3A6K (AAV6-CBD3A6K) expressing a fluorescent CBD3A6K (replacing A to K at position 6 of CBD3 peptide), which is an optimized variant of the parental CBD3 peptide that is a more potent blocker of Ca <sub>V</sub>2.2. Delivery of AAV6-CBD3A6K into lumbar (L) 4 and 5 dorsal root ganglia (DRG) of rats 2 weeks following tibial nerve injury (TNI) induced transgene expression in neurons of these DRG and their axonal projections, accompanied by attenuation of pain behavior. We additionally observed that the increased Ca <sub>V</sub>2.2α1b immunoreactivity in the ipsilateral spinal cord dorsal horn and DRG following TNI was significantly normalized by AAV6-CBD3A6K treatment. Finally, the increased neuronal activity in the ipsilateral dorsal horn that developed after TNI was reduced by AAV6-CBD3A6K treatment. Collectively, these results indicate that DRG-restricted AAV6 delivery of CBD3A6K is an effective analgesic molecular strategy for the treatment of established neuropathic pain. </p>

          Related collections

          Most cited references78

          • Record: found
          • Abstract: found
          • Article: not found

          Mechanisms of neuropathic pain.

          Neuropathic pain refers to pain that originates from pathology of the nervous system. Diabetes, infection (herpes zoster), nerve compression, nerve trauma, "channelopathies," and autoimmune disease are examples of diseases that may cause neuropathic pain. The development of both animal models and newer pharmacological strategies has led to an explosion of interest in the underlying mechanisms. Neuropathic pain reflects both peripheral and central sensitization mechanisms. Abnormal signals arise not only from injured axons but also from the intact nociceptors that share the innervation territory of the injured nerve. This review focuses on how both human studies and animal models are helping to elucidate the mechanisms underlying these surprisingly common disorders. The rapid gain in knowledge about abnormal signaling promises breakthroughs in the treatment of these often debilitating disorders.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Targeting voltage-gated calcium channels in neurological and psychiatric diseases.

            Voltage-gated calcium channels are important regulators of brain, heart and muscle functions, and their dysfunction can give rise to pathophysiological conditions ranging from cardiovascular disorders to neurological and psychiatric conditions such as epilepsy, pain and autism. In the nervous system, calcium channel blockers have been used successfully to treat absence seizures, and are emerging as potential therapeutic avenues for pathologies such as pain, Parkinson disease, addiction and anxiety. This Review provides an overview of calcium channels as drug targets for nervous system disorders, and discusses potential challenges and opportunities for the development of new clinically effective calcium channel inhibitors.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              alpha2delta expression sets presynaptic calcium channel abundance and release probability

              Synaptic neurotransmitter release is driven by Ca2+ influx through active zone voltage-gated calcium channels (VGCCs) 1,2 . Control of active zone VGCC abundance and function remains poorly understood. We show that a trafficking step likely sets synaptic VGCC levels as overexpression of the pore-forming α1A fails to change synaptic VGCC abundance or function. α2δs are a family of GPI-anchored VGCC-associated subunits 3 , which in addition to being the target of the potent neuropathic analgesics gabapentin and pregabalin (α2δ-1, α2δ-2) 4,5 , were also identified in a forward genetic screen for pain genes (α2δ-3) 6 . We show that these proteins confer powerful modulation of presynaptic function through two distinct molecular mechanisms. α2δ subunits set synaptic VGCC abundance, as predicted from their chaperone-like function when expressed in non-neuronal cells 3,7 . Secondarily, α2δs configure synaptic VGCCs to drive exocytosis through an extracellular metal ion-dependent adhesion site (MIDAS), a conserved set of amino acids within α2δ’s predicted von Willebrand A (VWA) domain. Expression of α2δ with an intact MIDAS motif leads to an 80% increase in release probability, while simultaneously protecting exocytosis from blockade by an intracellular Ca2+ chelator. α2δs harboring MIDAS site mutations still drive synaptic accumulation of VGCCs however, they no longer change release probability or sensitivity to intracellular Ca2+ chelators. Our data reveal dual functionality of these clinically important VGCC subunits, allowing synapses to make more efficient use of Ca2+ entry to drive neurotransmitter release. VGCCs are composed of pore-forming α1 and auxiliary β and α2δ subunits 8,9 . In central synapses neurotransmitter release is generally driven by P/Q-type (α1A) and/or N-type (α1B)10 VGCCs. Based on the failure of α1A overexpression to increase synaptic strength, it had been suggested that VGCCs functionally coupled to presynaptic release machinery is limited by a fixed number of available “slots” where channels can insert into the synaptic membrane 11 . We examined the existence of such a bottleneck by expressing eGFP-α1A12 together with a reporter of presynaptic exocytosis (vGlut1 with a luminal tag mOrange2, vGmOr2) and carried out retrospective immunocytochemistry to probe the abundance of α1A in transfected compared to control neurons. eGFP-α1A correctly trafficked to nerve terminals as it co-localized well with the vesicle-targeted reporter (Fig. 1a). In order to ensure eGFP-α1A functionally integrated with endogenous channels to drive neurotransmitter release we introduced a point mutation (E1656K), rendering this channel insensitive to the antagonist ω-agatoxin IVA 13 . Under control conditions a combination of ω-agatoxin IVA and the α1B inhibitor ω-conotoxin GVIA completely blocked vGmOr2 responses to action potential (AP) firing, however in the presence of eGFP-α1A E1656K a significant fraction of the response remains (Fig 1b). Measurements of single AP responses showed that expression of this exogenous α1A did not alter exocytosis efficiency compared to controls (Fig. 1c–d), consistent with the “slot” hypothesis 11 . However, retrospective immunocytochemistry using an anti-α1A antibody whose specificity was verified using shRNA-mediated α1A knockdown (Fig. S1) showed that transfected and control nerve terminals had similar immunoreactivity (Fig. 1e–f) while at the cell soma it had doubled (Fig S2). These results demonstrate that synaptic VGCC abundance is likely limited by trafficking from the cell soma and failure to increase synaptic performance does not result from a fixed number of active zone insertion sites. α2δ and β auxiliary VGCC subunits are both strong candidates for modulating such trafficking as they control functional expression of α1 subunits when co-expressed in non-neuronal cells 14,15 . We coexpressed individual auxiliary subunits with the reporter vGlut1-pHluorin (vGpH) in neurons and carried out measurements of exocytosis and immunocytochemistry as described above. These experiments demonstrated that expression of either α2δ-1 or β4 subunits led to a significant increase (~3-fold, p>0.05) in synaptic abundance of α1A (Fig. 1e–f). Similar results were obtained with overexpression of α2δ-2 (Fig. 1f). Furthermore, introduction of shRNA targeting α2δ-1 caused depletion of α1A at nerve terminals (Fig. 1e–f, Figure S3), while leaving the somatic concentration unaltered (data not shown). These results demonstrate that synaptic α1A levels are titrated by expression of auxiliary VGCC subunits. To examine whether changes in VGCC accumulation alters synaptic release properties, we measured single AP-stimulated exocytosis in neurons with altered VGCC levels. Overexpression and depletion of α2δ–1 led to much larger and much smaller single AP responses respectively compared to control (Fig. 2a). Similar increases in exocytosis were observed following expression of all three isoforms of α2δ tested (Fig. 2b). In contrast, expression of β4 did not change exocytosis, despite the synaptic accumulation of α1A (Fig. 2b). Quantitative estimates of α2δ-1 synaptic expression levels suggest a stoichiometric relationship between α2δ and α1A (Fig. S4). These results demonstrate that increasing VGCC abundance does not necessarily lead to increased function, and identify α2δ expression as a key rate-limiting parameter in determining presynaptic function. Measurements of presynaptic strength can be parsed into two biophysical parameters: the number of vesicles available for rapid release upon stimulation, known as the readily-releasable pool (RRP) and the probability that a vesicle in the RRP will undergo fusion with a single AP stimulus (Pv) 16 . We recently developed a rapid depletion protocol to measure RRP sizes using optical methods 17 . High frequency stimulation leads to rapid exhaustion of exocytosis in the first 8–15 APs. The fraction of the total pool corresponding to this rapid depletion phase is taken as the RRP 17 (Fig. 2c–d). The RRP size in neurons overexpressing α2δ was no different than controls (Fig. 2e). Thus α2δ overexpression changes Pv (Fig. 2f). α2δ-driven increases in Pv might arise from increasing total Ca2+ influx (from changes in VGCC gating and/or surface abundance) and/or changing VGCC proximity to release sites 18 . To examine this question, we measured intracellular [Ca2+] at synaptic boutons in response to single APs using the fast fluorescent indicator of Ca2+, Fluo5F-AM, visualized by expression of VAMP-mCherry (VAMPmCh; Fig. 3a left panel) with or without α2δ. Single APs resulted in robust Ca2+ signals (Fig. 3a right panel) that peaked within 1 ms. but were reduced by ~40% in synapses overexpressing α2δ isoforms compared to controls (Fig. 3b–c). We verified that the peak signal was not dominated by Ca2+ clearance mechanisms (e.g. endogenous buffers or extrusion) in experiments where the signal decay was set by high concentrations of intracellular EGTA. This treatment led to a ~50% decrease in peak signal and a decay time of ~10 ms in controls as well as α2δ overexpressing synapses. Measurements of Ca2+ signals using a genetically encoded Ca2+ indicator GCaMP3 19 , co-expressed with or without α2δ-1 gave very similar results (Fig. S5). This reduction in Ca2+ was surprising given that α2δ overexpression increases the total number of synaptic VGCCs (surface and intracellular) suggesting that α2δ might additionally control Ca2+ influx. Measurements of somatic AP waveforms revealed that α2δ expression led to a ~30% decrease in AP duration (Fig. S6), providing a possible explanation for the drop in synaptic Ca2+ entry. Given that exocytosis at nerve terminals is steeply dependent on Ca2+ influx 20 , the proximity of sites of Ca2+ influx to sites of exocytosis can, in principle, have a powerful influence over neurotransmitter release 2 . The increase in Pv with a commensurate decrease in Ca2+ influx strongly suggests that overexpression of α2δ subunits results in a tighter spatial relationship between sites of Ca2+ entry and exocytosis. We tested this hypothesis by measuring the sensitivity of exocytosis to the presence of a Ca2+ chelator (EGTA-AM). The chelator’s efficiency in reducing exocytosis depends on its ability to buffer Ca2+ before it binds the calcium-sensor for exocytosis following VGCC opening, a process determined by chelator concentration and Ca2+ binding kinetics 21 . We chose incubation conditions for EGTA-AM that led to a ~50% reduction in single AP exocytosis responses, compared to the pre-EGTA condition in control neurons (Fig. 3d). In neurons transfected with α2δ however, EGTA application led to much smaller decreases in exocytosis (Fig. 3e) indicating that in conditions of α2δ overexpression Ca2+ must bind the calcium sensor more rapidly than in control conditions. Therefore the Ca2+ sensor controlling exocytosis is experiencing higher levels of Ca2+ influx even though overall synaptic Ca2+ transients are reduced. Single AP-driven Ca2+ influx remained equally sensitive to ω-conotoxin GVIA following α2δ overexpression indicating this condition did not lead to a significant shift in VGCC type at nerve terminals (Fig. S7). The finding that α2δ subunits form GPI-anchored proteins 3 implies that their ability to change VGCC-exocytosis coupling is likely conveyed through an extracellular interaction. One possible candidate for exerting such influence lies in the highly-conserved VWA domain within α2δ 22 . A characteristic feature of this domain is its ability to interact with adhesion proteins via the MIDAS motif by sharing coordination of a divalent cation 23–25 . To examine the role of α2δ’s MIDAS motif we mutated three of five conserved key metal coordinating residues within the MIDAS motif to alanine 22 and expressed the mutant protein (α2δ-1 MIDASAAA) in neurons together with functional reporters. α2δ-1 MIDASAAA was similar to wild type α2δ-1 in its ability to drive α1A accumulation at synapses (Fig. 4a). However, measurements of exocytosis from α2δ-1 MIDAS-mutants showed no enhancement of Pv (Fig. 4b), normal Ca2+ influx (Fig. 4c) and normal sensitivity to EGTA block of exocytosis (Fig. 4d). Furthermore α2δ-2 MIDASAAA, unlike intact α2δ-2, was unable to rescue the decrease in exocytosis resulting from shRNA-mediated α2δ-1 depletion (Fig. 4e,f). These data are consistent with the ability of this mutation to block enhancement of Ca2+ currents when expressed in heterologous systems 22 (Fig. S8), but show that they do not prevent endogenous α2δ from functioning. Taken together, these results demonstrate that α2δ exerts its powerful control of synaptic VGCC function through at least two separate molecular mechanisms: a forward trafficking-step from cell body to presynaptic terminal that is independent of MIDAS motif integrity; and a local MIDAS-dependent interaction critical for proper VGCC function and coupling to exocytosis. α2δ-1 and α2δ-2 are the targets of the analgesic gabapentin whose binding site lies in close proximity to the MIDAS site 26 . We found no significant impact of gabapentin application (30 min and >72 h) on Pv in either control or cells overexpressing α2δ-1 or -2 (results not shown) similar to previous findings in hippocampal neurons 27 . We also examined gabapentin’s impact on VGCC trafficking to nerve terminals by incubating neurons with gabapentin from the time of transfection with eGFP-α1A. Analysis of the presynaptic abundance of this probe after 7 days showed that even though gabapentin appears to impact α2δ-2 trafficking in non-neuronal cells 28 it appears unable to impact VGCC trafficking or function in cultured hippocampal neurons (Fig. S9). Our results reveal that α2δ subunits are potent modulators of synaptic transmission. They function through at least two distinct molecular mechanisms: a trafficking step from the cell soma and a local step at the presynaptic terminal allowing synapses to exhibit increased exocytosis with decreased Ca2+ influx. We speculate that increased presynaptic abundance of VGCCs results in increased abundance of active zone-VGCCs, and hence a higher density in the vicinity of release sites. This active zone accumulation depends on α2δ’s VWA domain, presumably through interactions with extracellular active zone-specific proteins. The identity of the interaction partner(s) at present remains unknown however it is tempting to speculate that α2δs might recognize cues established in the correct juxtaposition of pre and postsynaptic membranes, consistent with synaptic defects observed in Drosophila α2δ-3 mutants 29 . Additionally this model requires that α2δ interact with a partner resulting in AP shortening to limit total calcium entry. As the MIDAS motif is well conserved throughout the α2δ family, identification of α2δ interaction partners in specific neuronal circuits could provide novel targets in the development of future therapeutics, given the potency that these subunits show in controlling synapse function. Methods Hippocampal CA3–CA1 regions were dissected from 1- to 3-day-old Sprague Dawley rats, dissociated, plated and transfected as previously described 30 . Live-cell images were acquired with an Andor iXon+ (model #DU-897E-BV) camera. A solid-state diode pumped 488 nm (vGpH and MgG imaging) or 532 nm (vGmOr2 imaging) laser was shuttered using acousto-optic modulation. For vGpH and GCaMP3 imaging data were acquired at 100 Hz by integrating for 9.74 ms in frame transfer mode and restricting imaging to a sub-area of the CCD chip. Fluo5F imaging data was acquired at 1 kHz (0.974 ms integration time). To estimate 1 AP ΔFs of vGpH, we took the difference between the average 20 frames before and after the stimulus. The rise in vGpH fluorescence in response to a single AP always took two frames when acquiring at 100 Hz time resolution. For display purposes the images in Fig. 1E were given a 2 pixel gaussian average filter. Pv and single AP calcium signals were measured with 4 mM extracellular CaCl2. All stated values are mean±SEM, statistical significance for groups of 3 or more were determined by one-way ANOVA with Tukey’s HSD for Post-Hoc analysis. Otherwise Student’s t-test was used for determining statistics. Supplementary Material 1 2
                Bookmark

                Author and article information

                Journal
                Gene Therapy
                Gene Ther
                Springer Science and Business Media LLC
                0969-7128
                1476-5462
                May 22 2019
                Article
                10.1038/s41434-019-0082-7
                6707887
                31118475
                d2e9f9b5-9e6c-4174-8314-84085174af96
                © 2019

                http://www.springer.com/tdm

                History

                Comments

                Comment on this article